Study Title: A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR A) in Patients
For more information about the trial above please contact the study team: